<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput xmlns:ns2="local" hits="1" offset="0" totalResults="1"><SearchResults><Drug id="54630" name="CM-AT" lastModificationDate="2017-09-28T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Curemark LLC</CompanyOriginator><CompaniesPrimary><Company>Curemark LLC</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Autism</Indication></IndicationsPrimary><ActionsPrimary><Action>Chymotrypsin modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Enzyme</Technology><Technology>Oral formulation</Technology></Technologies><Summary>Curemark is developing CM-AT, a formulation of digestive enzymes, for the potential oral treatment of autism in children with low levels of chymotrypsin in the bowels [ 640978 ], [ 640493 ]. In May 2009, a phase III trial was initiated in children with autism [ 1059426 ]. In September 2017, another phase III trial was ongoing and at that time, NDA submission was expected in 2018 [ 1964883 ]. The company was previously investigating the enzyme for ADHD [ 640978 ]; however, no further development has</Summary><IndicationsSecondary><Indication>Attention deficit hyperactivity disorder</Indication></IndicationsSecondary><ActionsSecondary><Action>Psychomodulator</Action></ActionsSecondary><AddedDate>2005-12-15T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="0" label="&lt; 100"></FilterOption><FilterOption count="0" label="≥ 100 and  250"></FilterOption><FilterOption count="0" label="≥ 250 and  500"></FilterOption><FilterOption count="0" label="≥ 500 and  1000"></FilterOption><FilterOption count="0" label="≥ 1000"></FilterOption></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="1"><FilterOption id="2940" count="1" label="Psychomodulator"></FilterOption></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="1"><FilterOption id="13" count="1" label="Drug - Funding"></FilterOption></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="0" label="&lt; 100"></FilterOption><FilterOption count="0" label="≥ 100 and  250"></FilterOption><FilterOption count="0" label="≥ 250 and  500"></FilterOption><FilterOption count="0" label="≥ 500 and  1000"></FilterOption><FilterOption count="0" label="≥ 1000"></FilterOption></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="0" label="= 0"></FilterOption><FilterOption count="1" label="&gt; 1 and ≤ 1"></FilterOption><FilterOption count="0" label="&gt; 2 and ≤ 2"></FilterOption><FilterOption count="0" label="&gt; 3 and ≤ 3"></FilterOption><FilterOption count="0" label="&gt; 4 and ≤ 4"></FilterOption><FilterOption count="0" label="&gt; 5 and ≤ 5"></FilterOption><FilterOption count="0" label="&gt; 6 and ≤ 10"></FilterOption><FilterOption count="0" label="&gt; 11"></FilterOption></Filter><Filter label="Technologies" name="technologies" total="3"><FilterOption id="761" count="1" label="Biological therapeutic"></FilterOption><FilterOption id="72" count="1" label="Enzyme"></FilterOption><FilterOption id="585" count="1" label="Oral formulation"></FilterOption></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="1"><FilterOption count="1" label="2005-12-15"></FilterOption></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="1"><FilterOption count="1" label="No"></FilterOption></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="1"><FilterOption id="423" count="1" label="Autism"></FilterOption></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="1"><FilterOption id="34" count="1" label="Attention deficit hyperactivity disorder"></FilterOption></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="1"><FilterOption id="2" count="1" label="Fast Track"></FilterOption></Filter><Filter label="Primary Actions" name="actionsPrimary" total="1"><FilterOption id="1282" count="1" label="Chymotrypsin modulator"></FilterOption></Filter><Filter label="Primary Companies" name="companiesPrimary" total="1"><FilterOption id="1018193" count="1" label="Curemark LLC"></FilterOption></Filter><Filter label="Highest Phase" name="phaseHighest" total="1"><FilterOption id="C3" count="1" label="Phase 3 Clinical"></FilterOption></Filter></Filters></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput>